Skip to main content

Table 4 Relationship between nuclear ADA3 and nuclear c-MYC co-expression groups with molecular biomarker status within ER+ tumors only (n = 432 cases)

From: ADA3 regulates normal and tumor mammary epithelial cell proliferation through c-MYC

Parameters ADA3 Nuclear C MYC Nuclear expression phenotypes
ADA3low C MYClow
N (%)
ADA3high C MYClow
N (%)
ADA3low C MYChigh
N (%)
ADA3high C MYChigh
N (%)
X 2 P
Patient age ≤50 35 (26.3) 18 (13.5) 39 (29.3) 41(30.8) 0.469 0.936
>50 78 (26.0) 38 (12.7) 82 (27.3) 102 (34.0)
Menopausal Status Pre 35 (24.5) 19(13.3) 44 (30.8) 45 (31.5) 1.002 0.8011
Post 78 (26.9) 37 (12.8) 77 (26.6) 98 (33.8)
Tumor size ≤2 cm 65 (24.3) 34 (12.7) 74 (27.6) 95 (35.4) 1.968 0.579
>2 cm 48(29.3) 22 (13.4) 45 (27.4) 49 (29.9)
Tumor grade 1 18 (22.0) 14 (17.1) 17 (20.7) 33 (40.2) 15.477 0.017
2 44 (25.6) 16 (9.3) 44 (25.6) 68 (39.5)
3 51 (28.5) 26 (14.5) 59 (33.0) 43 (24.0)
Tubules 1 5 (22.7) 7 (31.8) 5 (22.7) 5 (22.7) 9.813 0.133
2 41 (25.2) 17 (10.4) 51 (31.3) 54 (33.1)
3 65 (28.1) 27 (11.7) 60 (26.0) 79 (34.2)
Pleomorphism 1 1 (14.3) 1 (14.3) 3 (42.9) 2 (28.6) 19.460 0.003
2 52 (24.9) 31 (14.8) 42 (20.1) 84 (40.2)
3 58 (29.1) 19 (9.5) 71 (35.7) 51 (25.6)
Mitosis 1 40 (24.0) 22 (13.2) 38 (22.8) 67 (40.1) 10.175 0.117
2 23 (25.3) 8 (8.8) 30 (33.0) 30 (33.0)
3 48 (30.4) 21 (13.3) 48 (30.4) 41 (25.9)
Axillary nodal stage 1 58 (24.6) 35 (14.8) 61 (25.8) 82 (34.7) 3.652 0.724
2 43 (26.7 17 (10.6) 50 (31.1) 51 (31.7)
3 12 (32.4) 4 (10.8) 10 (27.0) 11 (29.7)
NPI Good 27 (18.6) 20 (13.8) 37 (25.5) 61 (42.1) 15.643 0.016
Moderate 63 (29.3) 31(14.4) 56(26.0) 65(30.2)
Poor 23 (31.5) 5(6.8) 27 (37.0) 18 (24.7)
Lymphovascular Invasion (LVI) Negative 75 (26.2) 44 (15.4) 67(23.4) 100 (35.0) 11.090 0.011
Positive 37 (25.3) 12 (8.2) 54 (37.0) 43 (29.5)
Tumor type Invasive Ductal/NST 71 (31.0) 28 (12.2) 71 (31.0) 59 (25.8) 44.333 <0.001
Invasive Lobular 13 (22.4) 8 (13.8) 4 (6.9) 33 (56.9)
Medullary-like 0(0) 1(33.3) 2 (66.7) 0 (0)
Excellent Prognostic Special types* 5 (26.3) 6 (31.6) 5 (26.3) 3 (15.8)
Tubular Mixed 16 (17.4) 11 (12.0) 28 (30.4) 37 (40.2)
Mixed NST & Lobular 4 (19.0) 2 (9.5) 6 (28.6) 9 (42.9)
Mixed NST &other special types 2 (28.6) 0 3 (42.9) 2 (28.6)
Ki67 labelling Index Low 35 (23.0) 25 (14.8) 33 (21.9) 68 (40.4) 11.217 0.011
High 49 (29.9) 22 (10.8) 38 (36.3) 50 (23.0)
p27 Low 61 (35.5) 21 (12.2) 47 (27.3) 43 (25.0) 18.993 <0.001
High 37 (16.9) 32 (14.6) 67 (30.6) 83 (37.9)
  1. N = number of cases. c. = cytoplasmic, n. = nuclear expression. NST = No Special Type. NPI = Nottingham Prognostic Index
  2. Analysis of ER+ patient specimens with respect to tumor grade, nuclear pleomorphism, NPI, LVI, histologic tumor type, Ki67 labeling index, and P27 demonstrated a statistically significant correlation across the four groups
  3. The bold font indicate that the clinical correlation is statistically significant < 0.05
\